Lilly's mirikizumab improves clinical remission in Phase II for ulcerative colitis

Eli Lilly and Co. (NYSE:LLY) reported in June that 200 mg IV mirikizumab (LY3074828) met the primary endpoint of improving clinical remission rate at week

Read the full 254 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE